来自Jan-Aushadi计划的通用吸入支气管扩展剂与品牌替代品的经济评估
Jerin James1, Neha Pillai Vinod2, Mridula Murali Manohar2
1SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, India. jerinj@srmist.edu.in.
Cost effectiveness and resource allocation : C/E
|September 27, 2025
概括
在印度,与品牌替代品相比,Jan Aushadhi通用吸入式支气管扩展器提供了显著的成本节省. 这项研究强调了它们在治疗呼吸系统疾病方面的可负担性,为许多人提供了财政支持.
科学领域:
- 药物经济学 药物经济学
- 公共卫生 公共卫生
- 呼吸系统医学 呼吸系统医学
背景情况:
- 印度呼吸系统疾病的高发病率需要负担得起的吸入式支气管扩展器.
- "人民健康计划"旨在以更低的成本提供优质的仿制药.
- 贫困人口面临经济障碍,无法获得必要的呼吸道药物.
研究的目的:
- 来自Jan Aushadhi药房的通用吸入支气管扩展剂与其品牌同行进行成本比较.
- 评估Jan Aushadhi仿制药对患者负担能力的经济影响.
- 为医疗保健决策者提供有关节省呼吸系统疾病管理成本的机会的信息.
主要方法:
- 对Jan Aushadhi通用支气管扩展剂和销售的品牌药物的比较成本分析.
- 确定药物成本的印度卢比相同的分子和剂量.
- 计算通用和品牌选项之间的成本差异,成本比率和成本差异.
主要成果:
- 所有的Jan Aushadhi通用吸入式支气管扩展剂被发现比它们的品牌同类药物便宜,除了一个例外 (Salmetrol).
- 酸铁显示出最高的成本差异和成本比率 (5.55) 和成本差异 (455.454).
- 在所研究的支气管扩展剂中,沙美特罗尔 (25mcg) 的成本差异是最小的.
结论:
- "人民医药"通用吸入式支气管扩展器提供了一个比昂贵的品牌药物更实惠的替代品.
- 将品牌支气管扩展剂替换为Jan Aushadhi通用药物可以为患者节省大量的财务成本.
- 这种成本比较为医疗保健政策和患者获得呼吸系统治疗的机会提供了宝贵的见解.
相关概念视频
01:23Inhaled Medications
749
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
749
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
179
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
179
01:28Adrenergic Agonists: Mixed-Action Agents
1.4K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.4K